Navigation Links
BioMarin to Present at the Morgan Stanley Healthcare Conference
Date:4/24/2008

NOVATO, Calif., April 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, Florida on Thursday, May 1, 2008 at 5:00 p.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutica
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... CHAPEL HILL, N.C., Aug. 22 Quality and ... year in light of,demands for higher efficiencies fueled ... issues on multiple fronts --,smaller pipelines are affecting ... increasing and harsher FDA regulations brought more scrutiny ...
... non-profit, faith-based and community organizations to ... proactively get the job done, ... agreement with a non-profit organization to utilize its,Ogiene(TM) FE technology to ... safely used by those families so desperately in need,of biohazard-free housing., ...
... Cellular Platform Utilizing Cord, Blood and Menstrual Blood Derived Stem ... ... Vascular Structures, OLDSMAR, Fla., Aug. 21 Cryo-Cell,International, ... research collaboration to co-develop a combined cellular,platform therapeutic for rapidly ...
Cached Biology Technology:Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 2Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 3Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 4
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... method to identify DNA mutations may shepherd in an ... screening and identification of genes that harbor disease. , ... Biosensors at the Biodesign Institute at ASU, led a ... of biosensors, electronics, and nanotechnology to fashion nanocrystals that ...
... provide for study of human immune responses, scientists have ... rapid immune response by two separate armies of defensive ... microbes like the leprosy bug, this initial defense sometimes ... yields to a dangerous, spreading infection. , Led by ...
... University of North Carolina at Chapel Hill is one ... the National Institutes of Health to study why good ... the next seven years, the Drug-Induced Liver Injury Network, ... liver injury caused by prescription and over-the-counter medications, nutritional ...
Cached Biology News:Bioelectronic ‘signatures?hold key to DNA mutations 2Leprosy microbes lead scientists to immune discovery 2UNC launches study of liver injury caused by drugs 2
... Sheep polyclonal to Decorin ( Abpromise ... Antigen: Synthetic peptide: ... amino acids 6-19 of Human Decorin ... bone proteoglycan II). ...
...
... NEW VSOS-4P, all Programmable and Digital Orbital Shaker. ... been redesigned to make every day use even ... memory for up to 4 different programs. Its ... your program. Furthermore, the VSOS-4P has a pulse ...
... plus,for Reliable Sterile Filtration of Tissue Culture ... pump or tube pump, quickly and,reliably sterilize ... aqueous solutions. The combination of a ... de-aeration,ensures high flow rates and optimal total,throughputs. ...
Biology Products: